Crump A (Kitasato University Graduate School of Infection Control Sciences), 2017-02-15: Review by Andy Crump that summarises laboratory anticancer findings under a short 'Anti-cancer' heading and describes ivermectin's potential as an antibacterial, antiviral and anti-cancer agent in strongly positive terms.
Ivermectin-induced cytostatic autophagy also leads to suppression of tumor growth in breast cancer xenografts, causing researchers to believe there is scope for using ivermectin to inhibit breast cancer cell proliferation and that the drug is a potential treatment for breast cancer.
Crump A (Kitasato University Graduate School of Infection Control Sciences), 2017-02-15: Review by Andy Crump that summarises laboratory anticancer findings under a short 'Anti-cancer' heading and describes ivermectin's potential as an antibacterial, antiviral and anti-cancer agent in strongly positive terms. C2. Review article, Japan (Kitasato University). Author is Crump alone, NOT Omura – the book's attribution of anticancer advocacy to Omura cannot rest on this paper. The passage summarises Dou et al. (Cancer Res 2016) and Sharmeen et al. (Blood 2010) lab work; it reports no clinical cancer data and gives no dosing. Same review states ivermectin 'was registered in 1987' (registration, not FDA approval) – relevant to F1. Nature.com page renders abstract, introduction and reference list to an automated fetch; the 'Anti-cancer' section text was returned by the page fetch and is quoted from there. Also filed as IVA-57 (claims C2, F1). Study type: review.
